We are live on ! Find out more
NMC

NEA Management Company Portfolio holdings

AUM $1.76B
1-Year Est. Return 223.33%
This Fund
S&P 500
This Quarter Est. Return
+22.8%
1 Year Est. Return
+223.33%
3 Year Est. Return
+769.45%
5 Year Est. Return
+668.45%
10 Year Est. Return
+14,843.34%
AUM
$2.23B
AUM Growth
+$301M
Cap. Flow
-$59.4M
Cap. Flow %
-2.66%
Top 10 Hldgs %
83.23%
Holding
40
New
1
Increased
3
Reduced
3
Closed
1

Top Buys

Rank Stock Value
1
ARDX icon
Ardelyx
ARDX
+$24M
2
KA
Kineta, Inc. Common Stock
KA
+$6.13M
3
XCOM
XTERA COMMUNICATIONS INC COM STK (DE)
XCOM
+$3.27M
4
OREX
Orexigen Therapeutics, Inc.
OREX
+$1.26M

Top Sells

Rank Stock Value
1
GRPN icon
Groupon
GRPN
+$63.5M
2
EXEL icon
Exelixis
EXEL
+$17.2M
3
LOXO
Loxo Oncology, Inc
LOXO
+$13.2M
4
ZSAN
Zosano Pharma Corporation
ZSAN
+$120K

Sector Composition

Rank Sector Weight
1 Healthcare 84.35%
2 Communication Services 4.64%
3 Technology 1.52%
4 Consumer Discretionary 1.46%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
VIRX
26
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
$5.67M 0.25%
37,094
– –
DZSI
27
DELISTED
DZS Inc. Common Stock
DZSI
$5.45M 0.24%
956,258
– –
ARQL
28
DELISTED
Arqule Inc
ARQL
$4.51M 0.2%
2,520,316
– –
ORKA
29
Oruka Therapeutics
ORKA
$5.82B
$4.13M 0.19%
6,760
– –
AKTX
30
Akari Therapeutics
AKTX
$13.8M
$3.85M 0.17%
565
– –
CSBR icon
31
Champions Oncology
CSBR
$74.5M
$2.63M 0.12%
1,562,500
– –
AVTX icon
32
Avalo Therapeutics
AVTX
$965M
$2.52M 0.11%
207
– –
ROKA
33
DELISTED
Sorrento Tech, Inc. Common Stock
ROKA
$2.22M 0.1%
322,043
– –
XCOM
34
DELISTED
XTERA COMMUNICATIONS INC COM STK (DE)
XCOM
$2M 0.09%
+3,631,537
New +$3.27M
ZSAN
35
DELISTED
Zosano Pharma Corporation
ZSAN
$1.6M 0.07%
2,933
-151
-5% -$120K
OREX
36
DELISTED
Orexigen Therapeutics, Inc.
OREX
$1.23M 0.06%
370,900
+333,810
+900% +$1.26M
AGRX
37
DELISTED
Agile Therapeutics
AGRX
$932K 0.04%
67
– –
PRTK
38
DELISTED
Paratek Pharmaceuticals, Inc.
PRTK
$862K 0.04%
66,245
– –
GYRE icon
39
Gyre Therapeutics
GYRE
$641M
$789K 0.04%
5,799
– –
EXEL icon
40
Exelixis
EXEL
$13.3B
– –
-2,207,000
Closed -$17.2M
1
2

Similar funds

NM
NWI Management New York $1.76B AUM 45.08% 1-Year Est. Return
SLF
Sun Life Financial Toronto, Ontario, Canada $1.76B AUM 19.57% 1-Year Est. Return
CCIA
Campbell & Co Investment Adviser Baltimore, Maryland $1.76B AUM 13.06% 1-Year Est. Return
SW
Simplicity Wealth Summit, New Jersey $1.76B AUM 20.49% 1-Year Est. Return
CGH
Contrarius Group Holdings Hamilton, Bermuda $1.77B AUM 83.15% 1-Year Est. Return
PWP
Principle Wealth Partners Madison, Connecticut $1.75B AUM 21.63% 1-Year Est. Return
CIP
CAS Investment Partners Westport, Connecticut $1.75B AUM 41.95% 1-Year Est. Return
GD
Grandfield & Dodd New York $1.77B AUM 23.43% 1-Year Est. Return

NEA Management Company's Q3 2016 Portfolio in Review

As of Q3 2016, NEA Management Company held 40 positions worth $2.23B, up 16% from $1.93B the previous quarter. Its ten largest holdings account for 83% of the portfolio.

NEA Management Company's Q3 2016 filing shows 1 new, 3 increased, 3 reduced and 1 closed positions. Its largest new stake was XTERA COMMUNICATIONS INC COM STK (DE): 3,631,537 shares worth $2M. The largest sale was Groupon, an estimated $63.5M.

By sector, the portfolio is most concentrated in Healthcare at 84% of assets, up from 83% a quarter earlier, followed by Communication Services and Technology.

  • NEA Management Company's largest Q3 2016 buy was XTERA COMMUNICATIONS INC COM STK (DE): 3,631,537 shares worth $2M.
  • NEA Management Company added most to Ardelyx in Q3 2016, an estimated $24M increase.
  • NEA Management Company's biggest Q3 2016 reduction was Groupon, cutting an estimated $63.5M.
  • NEA Management Company fully exited Exelixis in Q3 2016, selling an estimated $17.2M.
  • NEA Management Company's ten largest holdings make up 83% of its $2.23B portfolio in Q3 2016.
  • NEA Management Company opened 1 new position and closed 1 in Q3 2016.
  • NEA Management Company's portfolio value rose 16% quarter-over-quarter to $2.23B.

Based on NEA Management Company's 13F filing for Q3 2016, filed 10 Nov 2016.